NUCKS1, a novel Tat coactivator, plays a crucial role in HIV-1 replication by increasing Tat-mediated viral transcription on the HIV-1 LTR promoter by Hye-Young Kim et al.
Kim et al. Retrovirology 2014, 11:67
http://www.retrovirology.com/content/11/1/67RESEARCH Open AccessNUCKS1, a novel Tat coactivator, plays a crucial
role in HIV-1 replication by increasing
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Background: Human immunodeficiency virus-1 (HIV-1) Tat protein plays an essential role in HIV gene transcription
from the HIV-1 long terminal repeat (LTR) and replication. Transcriptional activity of Tat is modulated by several host
factors, but the mechanism responsible for Tat regulation by host factors is not understood fully.
Results: Using a yeast two-hybrid screening system, we identified Nuclear ubiquitous casein and cyclin-dependent
kinase substrate 1 (NUCKS1) as a novel Tat-interacting partner. Here, we report its function as a positive regulator of
Tat. In a coimmunoprecipitation assay, HIV-1 Tat interacted sufficiently with both endogenous and ectopically
expressed NUCKS1. In a reporter assay, ectopic expression of NUCKS1 significantly increased Tat-mediated
transcription of the HIV-1 LTR, whereas knockdown of NUCKS1 by small interfering RNA diminished Tat-mediated
transcription of the HIV-1 LTR. We also investigated which mechanism contributes to NUCKS1-mediated Tat
activation. In a chromatin immunoprecipitation assay (ChIP), knockdown of NUCKS1 interrupted the accumulation
of Tat in the transactivation-responsive (TAR) region on the LTR, which then led to suppression of viral replication.
However, NUCKS1 expression did not increase Tat nuclear localization and interaction with Cyclin T1. Interestingly,
the NUCKS1 expression level was lower in latently HIV-1-infected cells than in uninfected parent cells. Besides,
expression level of NUCKS1 was markedly induced, which then facilitated HIV-1 reactivation in latently infected cells.
Conclusion: Taken together, our data demonstrate clearly that NUCKS1 is a novel Tat coactivator that is required
for Tat-mediated HIV-1 transcription and replication, and that it may contribute to HIV-1 reactivation in latently
HIV-1 infected cells.
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Human immunodeficiency virus type-1 (HIV-1) encodes
a transcriptional activator (transactivator) protein, Tat,
which is essential for efficient transcription of the inte-
grated provirus following HIV-1 replication and for
disease progression [1,2]. Tat binds cooperatively to
transactivation-responsive (TAR) RNA, which is found
at the 5’ end of all HIV-1 viral RNAs with cellular fac-
tors, followed by transcriptional elongation [3]. Several* Correspondence: kmc755@korea.kr
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activity of Tat. Positive transcription elongation factor
b (P-TEFb) composed of Cyclin T1 (CycT1) and CDK9
is one of the most important factors promoting HIV-1
transcription. P-TEFb is connected to other transcrip-
tion elongation activators/co-activators including ELL2
and ENL/AF9 by scaffold protein AFF4/AFF1 to form a
larger super elongation complex (SEC). Tat selectively
recruits SEC to HIV-1 LTR to stimulate viral transcrip-
tion [4-7]. Subsequently, both elongation activators
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C-terminal domain of RNA polymerase II (Pol II) and
by preventing of its backtracking [8,9]. Although it has
also been reported that Tat activity is modulated by
Tat-interacting proteins such as Tip60, HT2A, CA150,
TFIID, Tat-SF1, Tip30, p300, CREB-binding protein,
PC4, and Tip110, which regulate Tat activity by regu-
lating its interactions with TAR RNA and/or other
host factors [10-20], the precise mechanisms under-
lying Tat regulation by these factors remain unclear. A
number of cellular transcription factors such as SP1,
nuclear factor κB (NF-κB), TBP, nuclear factor of activated
T cells (NFAT), USF, and nuclear receptor chicken ovalbu-
min upstream promoter transcription factor (COUP-TF),
also regulate the HIV-1 LTR promoter activity through
target elements located upstream of TAR RNA within the
LTR promoter [21-25].
HIV-1 gene expression is regulated by epigenetic
control by histone-modifying enzymes (HDAC, PCAF,
GCN5, SUV39H1, etc.), DNA methylation on the CpG
islands in the LTR, and nucleosome remodeling by
SWI/SNF of HIV-1 integrase [26-28]. Thus, it is be-
lieved that Tat–host cellular factor interactions, tran-
scription, and epigenetic factors form a complex
regulatory network for the regulation of HIV-1 gene ex-
pression in a diverse range of host cells and in response
to a variety of extracellular stimuli. Therefore, identifi-
cation of key factors for Tat-mediated HIV-1 gene ex-
pression may be required for understanding HIV
replication and for exploring potential targets of anti-
viral drugs [29,30].
Nuclear ubiquitous casein and cyclin-dependent kinase
substrate 1 (NUCKS1) is a nuclear DNA-binding protein
that is highly phosphorylated by casein kinase II (CK2),
cyclin-dependent kinases 1 (Cdk1), and DNA-activated
kinase [31,32]. NUCKS1 is expressed ubiquitously in
all mammalian tissues, and its apparent molecular mass
is ~28.4 kDa including posttranslational modifications.
However, its molecular mass appears to be 50 kDa in so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) [32]. NUCKS1 is synthesized in the M/G1
phase [33] and is highly expressed in several human
cancers including ovarian, lung, bone marrow, brain,
and breast cancer [34-36]. Even though NUCKS1 seems
to be important to the cell cycle and cancer progression,
its exact role has not been clarified.
We used the yeast two-hybrid screening system to ex-
plore the Tat regulatory mechanism in relation to the
host factors. Here, we report that NUCKS1 is a novel
Tat-interacting partner that induces Tat-mediated viral
transcription by accumulating Tat on TAR RNA regions
of the LTR promoter, which may then contribute to the
positive regulation of viral replication in HIV-1 latently
infected cells during reactivation.Results
NUCKS1 and Tat interact
To identify the binding partners of HIV-1 Tat, we used a
yeast two-hybrid screening with full-length HIV-1 Tat
(amino acids 1–86) as the bait together with the human
thymus cDNA library as the prey. From 44 positive clones
resulting from nutritional selection, one clone was found
to contain a cDNA of 732 bp (GenBank accession number
NM_022731) encompassing the full-length open-reading
frame of the NUCKS1 protein (Figure 1A). To determine
whether Tat interacts with cellular NUCKS1, Flag-tagged
HIV-1 proteins (Flag–Tat, -Vpr and -Nef) and V5-tagged
NUCKS1 (V5–NUCKS1) expression plasmids were intro-
duced into HEK293 cells individually (with each empty
vector) or in combination and then analyzed by coim-
munoprecipitation and a Western blot assay. Tat coim-
munoprecipitated with NUCKS1 in cells expressing
both Flag-Tat and V5-NUCKS1, but other HIV proteins
(Vpr and Nef ) did not (Figure 1B). Next, we tried to
confirm the endogenous interaction between Tat and
NUCKS1. As shown in Figure 1C, endogenous NUCKS1
was immuno-precipitated by the anti-Flag antibody in
Flag–Tat-expressing HEK293 cells, but not by the RNA
polymerase II antibody (Figure 1C). These results sug-
gest that Tat interacts directly with both ectopically
expressed and endogenous NUCKS1.
NUCKS1 facilitates Tat-mediated transcriptional activation
on the HIV-LTR
To determine whether the NUCKS1 has a functional role
in Tat-induced transcriptional activation on the HIV-1
LTR, HIV-1 LTR-driven luciferase and the NUCKS1
expression plasmid were introduced into HeLa cells in the
presence or absence of the Tat expression plasmid. Even
though Tat markedly increased the transcription of LTR,
expression of NUCKS1 increased this activity further by
more than 2.3-fold (Figure 2A). NUCKS1 alone had no
effect on the HIV LTR in the absence of Tat (Figure 2A).
Expression of increasing amounts of NUCKS1 increased
the Tat-mediated transcriptional activity on the LTR in a
dose-dependent manner without changing the amount of
Tat expressed (Figure 2B).
To examine the effect of the loss of function of
NUCKS1 in Tat-mediated transcriptional activation of
the HIV-1 LTR, knockdown of NUCKS1 was performed
with three siRNAs against NUCKS1, which effectively
decreased the expression level of NUCKS1 (Figure 2C).
Tat-mediated LTR activation was decreased significantly
by NUCKS1 knockdown with these siRNAs, whereas
NUCKS1 knockdown had no effect in the absence of
Tat, which was consistent with that showing no effect of
NUCKS1 expression (Figure 2D). These data demon-
strate that NUCKS1 plays a crucial role in the Tat-
mediated transcription on the HIV-1 LTR and suggest
Figure 1 Interaction between HIV-1 Tat and NUCKS1. (A) Tat-expressing plasmid cloned into pGBKT7 and NUCKS1 selected from human
thymus cDNA library cloned into pACT2 (Clontech) was transformed into the yeast strain PBN204. The transformants were grown on an SD plate
lacking adenosine and uracil for 48 h. Murine p53 and SV40 large T antigens were used as a positive control. Two panels show yeast colonies
showing the interaction of Tat and NUCKS1. (B) Ectopically expressed Tat interacts with ectopically expressed NUCKS1 in HEK293 cells. Two
micrograms of the Flag–Tat, Flag-Vpr and Flag-Nef expression vector were cotransfected with the V5–NUCKS1 expression vector into HEK293 cells
cultured in 100 mm plates. Forty-eight hours after transfection, cell lysates were immunoprecipitated with an anti-Flag monoclonal antibody (M2).
Immunoprecipitates were analyzed by Western blotting using an HRP-conjugated anti-V5 monoclonal antibody. The Flag- or V5-tagged pcDNA3
plasmid was added to equalize the total amounts of DNA. (C) Coimmunoprecipitation assay between endogenous NUCKS1 and ectopically
expressed Tat protein. The lysate from Tat-expressing HEK293T cells was immunoprecipitated with anti-Flag and -Pol II antibodies, and the
interaction was assessed with Western blotting using anti-NUCKS1 or anti-Flag antibody.
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NUCKS1-mediated Tat activation is not cause by
activation of NF-κB, Tat nuclear localization and Tat–Cyc
T1 interaction
We next explored the mechanism by which NUCKS1
regulates Tat. Since NF-κB activation is required in the
early step of HIV-1 LTR transcription, we examined
whether NUCKS1 could regulate NF-κB activation. As
shown in Figure 3A, neither nuclear p65 nor cytoplasmic
IκB levels changed when NUCKS1 was expressed. This
contrasted with the effects of phorbol myristate acetate
(PMA) treatment following p65 nuclear localization and
degradation of IκB (Figure 3A). As a complementary ap-
proach, we assessed the NF-κB response element (RE)-
driven promoter activity in association with NUCKS1
expression and PMA treatment in HeLa cells. A pro-
moter harboring the NF-κB RE was not responsible forNUCKS1 expression, whereas its activity was increased
markedly by PMA treatment (Figure 3B). These data in-
dicate that NF-κB is not involved in NUCKS1-mediated
Tat activation.
We next attempted to determine whether NUCKS1 fa-
cilitates Tat nuclear localization because NUCKS1 is a
known nuclear protein containing two nuclear-localization
signals [31]. As shown in Figure 3C, both NUCKS1 and
Tat localized mainly to the nucleus when expressed either
alone or together in HeLa cells (Figure 3C). Cyc T1 inter-
action with Tat is essential for HIV-1 transcription. We
next wanted to determine whether NUCKS1-mediated Tat
activation is caused by enhancement of Tat–Cyc T1 inter-
action. We introduced the Flag–Tat and V5–NUCKS1 ex-
pression plasmids into HeLa cells, as shown in Figure 3D.
Flag–Tat was then immunoprecipitated from the cell
lysates. Tat bound simultaneously to NUCKS1 and Cyc
T1, and the Tat–Cyc T1 interaction was not interrupted
by NUCKS1 expression (Figure 3D). These data suggest
Figure 2 NUCKS1-mediated Tat activation on HIV-1 LTR. (A) One hundred nanograms of the Flag–Tat and/or 3 μg of the NUCKS1 expression
plasmid was transfected with 200 ng of the HIV-1 LTR-driven luciferase reporter (pGL3–LTR–Luc) and 20 ng of pCMV–LacZ as a transfection control into
HeLa cells. At 24 h after transfection, luciferase activity was measured and normalized to β-galactosidase activity. The data are expressed as mean ± SD
(n = 3). *, P < 0.01 as compared with the Flag-Tat transfected only. Expression levels of NUCKS1 and Tat were assessed with Western blotting.
(B) Luciferase activity was assessed in HeLa cells 24 h after cotransfection of pGL3–LTR–Luc (200 ng), Flag–Tat (100 ng), and increasing amounts
of V5–NUCKS1 (0, 0.5, 1, 2, and 3 μg), together with 20 ng of pCMV–LacZ as a transfection control. The data are expressed as mean ± SD (n = 3).
*, P < 0.01 and **, P < 0.05, as compared with the Flag-Tat transfected only (C) Knockdown of NUCKS1 was performed with three siRNAs against
NUCKS1 mRNA. HeLa cells were transfected with control siRNA or three NUCKS1 siRNAs. At 48 h after transfection, knockdown of NUCKS1 by siRNA
was assessed by Western blotting using anti-NUCKS1, anti-Flag and anti-β-actin antibodies as a loading control. (D) NUCKS1-engaed Tat activity was
assessed by the luciferase assay combined with the knockdown experiment. HeLa cells were transfected with control siRNA or three NUCKS1 siRNAs.
Twenty-four hours after transfection, cells were transfected further with pGL3–LTR–Luc, pCMV–LacZ, and Flag–Tat. The luciferase assay was conducted
as described in A. The data was expressed as mean ± SD (n = 3). *, P < 0.01 as compared with the cells transfected with control siRNA.
Kim et al. Retrovirology 2014, 11:67 Page 4 of 14
http://www.retrovirology.com/content/11/1/67that NUCKS1-mediated Tat activation may not be associ-
ated with the increase in Tat–Cyc T1 interaction.
NUCKS1 enhances the association of Tat to the TAR
sequence
To identify the possible mechanism underlying NUCKS1-
mediated Tat activation of the HIV-1 LTR, we next used
a ChIP assay with knockdown of NUCKS1. NUCKS1
siRNA was transfected into HeLa cells introduced with
the HIV-1 LTR, and chromatin was then immunopreci-
pitated with Tat. A chromatin coding TAR RNA in LTR
was immuno-precipitated with Tat, while other regions
were not (Additional file 1: Figure S1A). The depletion
of NUCKS1 by three independent siRNAs significantly
reduced the level of Tat associated with the chromatin
coding TAR RNA, conceivably by reducing the amountof Tat bound to TAR RNA (Figure 4A). Similar effects
were observed in TZM-bl cells integrated with HIV
LTR-driven β-galactosidase and luciferase reporter cas-
settes (Figure 4B and Additional file 1: Figure S1B). The
reduction of the amount of Cyclin T1 in the TAR-RNA
region, which might have been caused by the loss of
Tat in LTR, was observed by NUCKS1 knockdown in
both cells (Figure 4C and D). These data suggest that
NUCKS1 is closely associated with the interaction
between Tat and the TAR RNA region in both inte-
grated and unintegrated LTRs during Tat-induced HIV-1
transcription.
NUCKS1 plays a key role in viral production
Because HIV-1 Tat activity is essential for HIV-1 produc-
tion and replication, we thought that NUCKS1-mediated
Figure 3 Mechanism linked to NUCKS1-mediated Tat activation. (A) HeLa cells were transfected with the V5–NUCKS1 expression plasmid. At
24 h after transfection, some of the cells were treated with PMA (50 ng/ml) for 15 min before harvest, and the cells were harvested. Nucleus and
cytoplasm from the cells were fractionated. NF-κB activity was assessed by Western blotting using anti-p65, -Iκb, and -NUCKS1 antibodies. The
nuclear and cytoplasmic fractions were evaluated using anti-lamin B and -tubulin antibodies, respectively. (B) NUCKS1-mediated NF-κB promoter
activity was assessed by luciferase assay. HeLa cells transfected with NF-κB luciferase reporter plasmid (500 ng), V5–NUCKS1 (3 μg), and pCMV–LacZ
(20 ng). The luciferase assay was performed 24 h after transfection. PMA (50 ng/ml) treatment was used as a positive control. The data are expressed as
mean ± SD (n = 3). (C) HeLa cells were cotransfected with the Flag–Tat and V5–NUCKS1 expression plasmids. Twenty-four hours after transfection, the
nucleus and cytoplasm were fractionated, and the subcellular localization of Tat and NUCKS1 was assessed with Western blotting using anti-Flag,
anti-V5, -lamin B, and -α-tubulin antibodies, respectively. (D) HeLa cells were transfected with Flag–Tat, V5–NUCKS1, or both. Two days after
transfection, cell lysates were immunoprecipitated with anti-Flag antibody. Cyc T1–Tat interaction was assessed with Western blotting using
anti-Cyclin T1 and anti-Flag antibodies, respectively.
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tion. We compared the amount of viral antigen p24gag in
culture medium of HeLa cells transfected with infectious
molecular clone pNL4-3 (CXCR4-tropic) with that from
cells transfected with pAD8 (CCR5-tropic) combined with
three NUCKS1 siRNAs. CXCR4 (pNL4-3)- and CCR5
(pAD8)-tropic virus production was reduced markedly by
knockdown of NUCKS1 at different time points (0–5
days) (Figure 5A and B). We next compared the p24 levels
from replication competent A3.01 and Jurkat cells infected
with pNL4-3 combined with NUCKS1 knockdown. As
shown in Figure 5C, the levels of p24 from those cells
were decreased by NUCKS1 knockdown. These results in-
dicate that NUCKS1 is required for HIV-1 replication and
production involving Tat activity regardless of the tropism.
NUCKS1 plays an important role in reactivation of
provirus of HIV-1 latently infected cells
HIV-1 latency is characterized by long-term silent infec-
tion, which contributes to the HIV-1 pathogenesis [37].However, the mechanism is not understood fully. There-
fore, we attempted to link the NUCKS1-induced HIV-1
replication to viral reactivation from latent HIV-1 infec-
tion. We compared the mRNA and protein levels of
NUCKS1 between normal and latently HIV-1 infected
cell lines. As shown in Figure 6A, the NUCKS1 mRNA
level was significantly lower in HIV-1 latently infected
cells (ACH-2 and J1.1) compared with the normal parent
cells (A3.01 and Jurkat) (Figure 6A). Western blotting
of NUCKS1 indicated that latently infected cells ex-
pressed less NUCKS1 protein compared with normal
cells (Figure 6B).
Next, we investigated whether NUCKS1 expression was
increased in latently infected cells during PMA-induced
reactivation. The NUCKS1 protein level was increased
markedly in latently infected cells in a time-dependent
manner during HIV-1 proviral reactivation, as indicated
by the HIV p24 antigen production in the supernatant
treated with PMA. However, no significant change in
NUCKS1 protein level was found in the parent A3.01 and
Figure 4 Close association between NUCKS1 and Tat binding to TAR RNA. HeLa cells transiently transfected with HIV-1 LTR (A and C) or
TZM-bl cells containing an integrated HIV-1 LTR (B and D) were transfected with control siRNA or three individual NUCKS1 siRNAs. At 24 h after
knockdown, these cells were transiently transfected with the Flag–Tat expression plasmid and cultured for an additional 24 h. Cells were cross-linked
with formaldehyde, and chromatin immunoprecipitation was performed using IgG control or anti-Flag antibody (A and B) or anti-Cyclin T1 (C and D).
Quantitative real-time PCR was performed; the data were normalized to the IgG control antibody and are expressed as fold change of Tat
binding activity compared with control siRNA-treated samples. The data are expressed as mean ± SD (n = 3). *, P < 0.01 as compared to the cells
transfected with control siRNA.
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expression level of NUCKS1 mRNA increases due to
PMA treatment, mRNA sequencing was performed in a
latently infected cell line in the presence or absence of
PMA. The transcriptomic analysis showed that the level of
NUCKS1 mRNA was not changed under PMA treatment
for 48 h, even if other genes were relatively changed as
previously reported [38], except SLC15A4 (Figure 6D,
Additional file 2: Figure S2 and Additional file 3: Table S1).
Additionally, bisulfite sequencing of the CpG island
in the NUCKS1 promoter showed that the expression
of NUCKS1 was not regulated by epigenetic control
(Additional file 4: Figure S3). These data indicated that
the transcription of NUCKS1 is not associated with the
activation of latently infected cells by PMA treatment.Next, we examined whether NUCKS1 alone induces
HIV-1 production without NF-κB activation. As shown
in Figure 6E, NUCKS1 overexpression moderately induced
HIV-1 production without PMA stimulation. The data
may suggest that NUCKS1 can enhance Tat-mediated
HIV production without NF-κB activation. To examine
further whether NUCKS1 plays an essential role in
HIV-1 replication during proviral reactivation in latently
infected cells, we conducted NUCKS1 knockdown by
electroporation using specific siRNA in latently infected
ACH-2 cells and J1.1 cells under PMA-induced reactiva-
tion. Western blot analysis using NUCKS1-specific anti-
body showed the efficiency of the knockdown (Figure 6F
and G lower panel). Notably, p24 levels were decreased
significantly by knockdown of NUCKS1 in ACH-2 and
Figure 5 Key role of NUCKS1 in viral production and replication. (A-B) In the single-round replication assay, HeLa cells were transfected with
control siRNA or three individual NUCKS1 siRNAs. One day later, the cells were transfected with pNL4-3 (A) or pAD8 (B) proviral DNA. Two days
after siRNA transfection, the virus-containing supernatants were harvested every day for 5 days. The amount of virion in the supernatant was
measured by HIV-1 p24 ELISA. (C) In the viral replication assay, Jurkat and A3.01 cells were transfected with control siRNA or three individual
NUCKS1 siRNAs. One day later, the cells were infected with pNL4-3 virus. Five days after infection, the virus-containing supernatants were
harvested, and then the amount of virions in the supernatant was measured by HIV-1 p24 ELISA. The data are expressed as mean ± SD (n = 3).
*, P < 0.01 as compared with the cells transfected with control siRNA. The lower panels show the intracellular p24 levels.
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knockdown caused an average decrease of 60% in p24
concentration in ACH-2 cells and 82% in J1.1 cells
(Figure 6F and G upper panel). These data show that
NUCKS1 is a key regulator of HIV-1 latency and that it
plays an important role in HIV-1 reactivation from
latently infected cells.
Discussion
Defining the protein–protein interactions underlying the
dynamics of virus–host interactions is critical for under-
standing the molecular pathogenesis of HIV-1 infection.
In this study, NUCKS1 was identified as a novel Tat-
interacting protein in a yeast two-hybrid screening system.
The interaction between Tat and NUCKS1 was confirmedby coimmunoprecipitation associated with both ectopic
and endogenous expression (Figure 1). We have shown
here that ectopic expression of NUCKS1 efficiently in-
creased Tat-dependent transactivation of the HIV LTR in
a dose-dependent manner. Additionally, siRNA-induced
downregulation of endogenous NUCKS1 significantly
reduced Tat-mediated transcriptional activation on the
HIV-1 LTR promoter (Figure 2). These data indicate
that NUCKS1 is a potential candidate as a Tat coactiva-
tor that facilitates interactions between Tat and the
transcription machinery on the HIV-1 LTR.
Several studies have suggested that NUCKS1 may be
involved in facilitating and regulating cellular transcrip-
tional activity. Schaner et al. reported that the ubiquity






Figure 6 (See legend on next page.)
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Figure 6 Requirement of NUCKS1 for reactivation of provirus from HIV-1 latently infected cells. (A) Heatmap of mRNA expression of
NUCKS1 and other Tat-interacting factors. (B) Expression level of endogenous NUCKS1 in HIV-1 latent cells (ACH-2 and J1.1) and their parent cell
lines (A3.01 and Jurkat) were assessed with Western blotting using anti-NUCKS1 and anti-β-actin antibodies. The protein level of NUCKS1 was
calculated by densitometry (Image Gauge Version 4.0, FujiFilm) (C) Normal and latently infected cells were treated with PMA (50 ng/ml) for
indicated time. PMA-treated cell lysates were assessed by Western blotting using indicated antibodies. The levels of HIV-1 p24 were measured
using an HIV-1 p24 ELISA kit. The data are expressed as mean ± SD (n = 3). (D) mRNA-sequencing analysis. The RPKM (Reads Per Kilobase of exon
model per Million aligned tags) was calculated for each transcript. The Y-axis represents the log2 fold changes between the control and
PMA-treated ACH-2 cells. The right panel shows the expression level of NUCKS1 mRNA by RT-PCR. (E) ACH-2 and J1.1 cells were electrophorated
with V5 or V5-NUCKS1. Three days later, the amount of virion in the supernatant was measured by HIV-1 p24 ELISA kit. The right panel shows the
level of NUCKS1 expression by Western blotting. The data are expressed as mean ± SD (n = 3). *, P < 0.01 as compared to cells transfected with
empty vector. (F-G) ACH-2 (F) and J1.1 cells (G) were electroporated with control or three individual NUCKS1 siRNAs. At 48 h after knockdown,
the cells were treated with PMA (50 ng/ml) for 24 h and the levels of HIV-1 p24 were measured using an HIV-1 p24 ELISA kit. The data are
expressed as mean ± SD (n = 3). *, P < 0.01 as compared to the cells transfected with control siRNA.
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role in cell growth [34-36].
NUCKS has been reported to have 19 phosphorylation
sites, at least nine of which are phosphorylated by CK2
[39]. Candidates for CK2 substrates are likely to comprise
a functional link to transactivation of viral transcription.
For example, the Tat-SF1 and TRP-185 cofactors that
regulate HIV-1 transcription contain more than 12 and
20 CK2 phosphorylation sites, respectively [17,40].
Similarly, SRB, a protein that stimulates TRP-185 bind-
ing to TAR RNA, has 10 putative CK2 sites [41]. CK2
may be linked functionally to some proteins involved in
the replication of HIV-1 and stimulation of virally infected
cells [42-45]. However, CK2 activity that is specifically
linked to NUCKS1 in HIV-1 replication remains a subject
for further study.
Although the essential role of Tat during HIV transcrip-
tional activation is well established, NF-κB also stimulates
the transcription of HIV-1 LTR in the initiation step.
Thus, we could not exclude a possible role of NF-κB acti-
vation in NUCKS1-induced HIV-1 transcription together
with Tat expression (Figure 2). Therefore, we investigated
whether NUCKS1 increases HIV-1 transcriptional activity
in association with NF-κB activation. The expression of
NUCKS1 had no effect on nuclear translocation of p65,
degradation of IκBα, or NF-κB luciferase activity. Further-
more, the expression of NUCKS1 in latently HIV-1 in-
fected cell lines considerably induced HIV-1 production
without PMA-induced NF-κB activation (Figures 3A, B
and 6E). These data suggested that NUCKS1 increased
Tat-mediated transcriptional activity of the HIV-1 LTR in
an NF-κB-independent manner. On the other hand, the
expression level of NUCKS1 was not enhanced in primary
CD4+ T cell activated with anti-CD3/CD28, even though
NF-κB was significantly activated in the cells (Additional
file 5: Figure S4). These data revealed that NUCKS1 ex-
pression was not associated with the NF-κB pathway.
Tat-dependent transactivation of the HIV-1 LTR re-
quires three steps: 1) facilitation of nuclear localization
of Tat, 2) Tat–Cyc T1 interaction, and 3) docking ofTat–TAR RNA on the HIV LTR. However, subcellular
fractionation and coimmunoprecipitation analysis revealed
that NUCKS1 had no effect on Tat nuclear localization
and the stability of the Tat–Cyc T1 complex, respectively
(Figure 3C and D). This observation suggests that the
nuclear localization of Tat and the formation of the
Tat–P-TEFb complex are not the functional targets of
NUCKS1. Importantly, the ChIP assay showed that
knockdown of NUCKS1 decreased the accumulation of
Tat at the TAR region on the LTR, suggesting that
NUCKS1 promotes Tat-mediated transactivation by in-
creasing Tat–TAR interactions (Figure 4). However, the
detailed mechanism by which NUCKS1 regulates Tat–
TAR interaction remains unknown. It is possible that
NUCKS1 facilitates the interaction of Tat and TAR
RNA through chromatin structural remodeling in the
LTR region because NUCKS1 is a nuclear protein har-
boring a DNA-binding domain and it may be involved
in multiple transcriptional activities [46].
In this study, we used an HIV-1 production assay to
examine the influence of NUCKS1 on HIV-1 replica-
tion. Knockdown of NUCKS1 significantly decreased
the production of both CXCR4 (pNL4-3)- and CCR5
(pAD8)-tropic viruses (Figure 5A and B). Moreover, the
HIV-1 replication assay in A3.01 and the Jurkat cells in-
fected with pNL4-3 showed a significant reduction in
the level of HIV-1 p24 caused by NUCKS1 knockdown
(Figure 5C). This result showed that NUCKS1 regulated
the HIV-1 gene expression directly followed by HIV-1
virion production. Although this was consistent with
the NUCKS1-mediated Tat regulation described above,
it was insufficient to explain the transcriptional activation
leading to proviral reactivation from latently infected cells.
After infection, the provirus successfully integrates
into the host chromosome, and HIV-1 latency is estab-
lished by limiting the levels of several host factors and
interfering transcription. We used an mRNA microarray
assay to examine HIV-1-latent cell lines (Figure 6). Posi-
tively Tat-regulating factors such as CCNT1, protein
phospatase 1(PP1), and p300/CBP did not have lower
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cells, suggesting that the basal expression of these factors
may not be associated with latent infection [47,48]. Nega-
tively Tat-regulating factors including BanF1, BRD7, and
thioredoxin reductase-1 (TXNRD1) did not show consist-
ent differences in their expression patterns between latent
and normal cells [49-51]. Of these factors, only NUCKS1,
as a positively Tat-regulating factor, was expressed at a
lower level in latently infected cells than in normal parent
cells (Figure 6A and B). It has been reported that HIV-1
Tat regulating factors such as Cyclin T1 and CDK9 were
regulated by T cell receptor activation, which were
expressed at an extremely lower level and exhibited re-
stricted activity in primary resting cells [52,53]. Al-
though the expression profile of these factors from our
latency model using quickly dividing cell lines was
quite different from that of tightly regulated primary
resting memory T cells, our data may suggest that a
low expression level of NUCKS1 seems to be important
for maintaining latent infection characterized by re-
stricted HIV-1 gene expression in the cell line model.
HIV-1 latency is a major barrier to HIV-1 eradica-
tion and a critical source for rebound of viral load
after the interruption of highly active antiretroviral
therapy (HAART). Thus, it is important to identify the
host factors that can modulate latent HIV-1 infection
[37]. We identified a role of NUCKS1 in the reactiva-
tion process in HIV-1 latently infected cells treated
with PMA. The protein levels of NUCKS1 were in-
creased markedly in HIV-1 latently infected cells at
the same time that HIV-1 replication increased in a
time-dependent manner (Figure 6C). The reactivation
was increased by overexpression of NUCKS1 without
NF-κB activation (Figure 6E) and was reduced markedly
by knockdown of NUCKS1 (Figure 6F and G), indicating
that NUCKS1 is needed for HIV-1 reactivation. These
results show that NUCKS1 might be a novel host factor
that increases viral replication by activating ‘silent’
viruses.
Conclusions
In summary, our study shows that NUCKS1: i) increases
the Tat-mediated transcription of the HIV-1 LTR in an
NF-κB-independent manner ii) facilitates the interaction
of Tat with TAR RNA in the LTR, and iii) plays an import-
ant role in the reactivation of latent HIV-1 infection.
Taken together, our data suggest that NUCKS1 plays
an important regulatory role in Tat-mediated HIV-1
transcription by facilitating the process of HIV-1 repli-
cation and/or awaking from the HIV-1 latency state.
Further understanding of the mechanism responsible
for NUCKS1-mediated Tat regulation may be helpful in
the development of potent new anti-HIV-1 drugs and for
strategies for purging HIV-1 from the latency reservoir.Methods
Cells, viruses, and plasmids
HeLa, HEK293, TZM-bl, A3.01, ACH-2, Jurkat, and J1.1
cells were obtained through the NIH AIDS Research and
Reference Reagent Program and American Type Culture
Collection (ATCC). HeLa, HEK293, and TZM-bl cells
were maintained in Dulbecco’s modified Eagle medium
(DMEM; Gibco-BRL). ACH-2 and J1.1 are chronically
infected cell lines harboring the HIV-1 LAV strain, and
A3.01 and Jurkat are the corresponding uninfected par-
ent cell lines. Cells were maintained in RPMI medium
(Gibco-BRL). All cells were supplemented with 10% fetal
bovine serum (FBS; Gibco-BRL), 1% L-glutamine, and
1% penicillin–streptomycin. Human PBMCs were isolated
from blood samples by Ficoll-Hypaque 1.077 (Sigma),
and CD4+ T cells were purified from the PBMCs using
a CD4+ T cell isolation kit (Miltenyi Biotec) according
to the manufacturer’s instructions. The HIV-1 molecu-
lar clone pNL4-3 was obtained through the NIH AIDS
Research and Reference Reagent Program, and pAD8
was kindly provided by Dr Young-bong Kim, Konkuk
University, Seoul, South Korea. Tat-expressing plasmid
was constructed by cloning wild-type Tat (HXB2 strain)
cDNA into the pcDNA3-Flag (Invitrogen) plasmid. The
NUCKS1-expressing plasmid was constructed by cloning
the pcDNA3-V5 (Invitrogen) plasmid. The pGL3–LTR
plasmid contains a luciferase gene driven by the HIV-1
LTR and was used in the Tat-mediated transactivation
reporter assay.Knockdown of NUCKS1
Knockdown of NUCKS1 was performed with small
interfering RNA (siRNA) corresponding to NUCKS1
(si–NUCKS1) synthesized using the following three
oligonucleotide sequences: #1; 5’-GAAGGUUGUUG
AUUACUCACAGUUU-3’, #2; 5’-GGAUGAUUCUCA
CUCAGCAGAGGAU-3’, and #3; 5’-GGCGGCAUCU
AAAGCAGCUUCUAAA-3’, and nontargeting siRNA
(si–con) purchased from Invitrogen. In brief, HeLa
cells were transfected with 200 pmole siRNA using
Lipofectamine 2000 reagent (Invitrogen). Twenty-four
hours after transfection, cells were cotransfected with
pcDNA3–Flag–Tat, pGL3–LTR, and pCMV–LacZ using
Lipofectamine 2000 reagent. Forty hours after cotransfec-
tion, total cell lysates were harvested for determination of
luciferase activity using the luciferase reporter assay
system (Promega) on a SpectraMax M5 microplate
luminometer (Molecular Devices). Knockdown of HIV-1
latently infected cells (ACH-2 and J1.1 cells) was per-
formed by electroporation using a Nucleofector™ kit X
(Lonza) according to the manufacturer’s protocol (18, 40).
The expression level of NUCKS1 was analyzed by Western
blotting using anti-NUCKS1 antibody (Novus Biologicals).
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Yeast two-hybrid screening was conducted using the
Matchmaker GAL4 two-hybrid system 3 (Clontech) as
described previously [54]. In brief, the region containing
full-length Tat was generated by PCR, cloned down-
stream of the GAL4 DNA-binding domain in pGBKT7
(pGBKT7–Tat/bait), and introduced into the yeast strain
PBN204 containing three reporters (URA3, ADE2, and
LacZ), which are under the control of different GAL
promoters. The transformants of the Tat bait and the
human thymus cDNA activation domain library were
screened on selection medium lacking leucine, tryptophan,
and uracil, which support the growth of yeast when the
bait plasmid and the prey proteins interact with each
other. After selection of the putative Tat-binding protein,
NUCKS1, the amplified NUCKS1-expressing prey plasmid
was reintroduced into the yeast PBN204 strain with
the Tat bait plasmid to confirm the interaction of
Tat–NUCKS1.
Luciferase reporter assays
HeLa cells were cultured on 12-well plates (2.5 × 105 cells/
well) for 1 day before transfection. The cells were trans-
fected with 0.05 μg of pcDNA3–Flag–Tat, 0.2 μg of
pGL3–LTR–Luc, and different amounts of pcDNA3–V5–
NUCKS1 plasmids using Lipofectamine 2000 reagent
(Invitrogen). pCMV–LacZ (0.02 μg) was cotransfected as
a transfection control. The luciferase assay was performed
as described previously [55]. In brief, the cell medium
was replaced with fresh medium 4 h after transfection.
Twenty-four hours after transfection, luciferase activ-
ity was measured using a luciferase reporter assay sys-
tem (Promega) in a DTX 880 MultiMode Detector
(Beckman Coulter). Luciferase activity was normalized
to β-galactosidase activity. The data are represented as
mean ± SD (n = 3).
Coimmunoprecipitation
The coimmunoprecipitation assay was performed as
described previously [56]. Briefly, HEK293 cells were
transfected with Tat-expressing plasmids (pcDNA3–
Flag–Tat) and NUCKS1-expressing plasmids (pcDNA3–
V5–NUCKS1) using Lipofectamine 2000 (Invitrogen).
After 48 h, cells were lysed in immunoprecipitation buffer
(250 mM NaCl, 0.5% NP-40, 50 mM Tris-HCl [pH 7.5],
5 mM EDTA, 1 mM Na3VO4, 10 mM NaF, and protease
inhibitor cocktail). Cell lysates were incubated with anti-
Flag monoclonal antibody (M2; Sigma) at 4°C. After over-
night incubation, protein A/G agarose beads (Santa Cruz
Biotechnology) were added, and the mixture was incu-
bated for 1 h at 4°C and then centrifuged at 2,500 × g at
4°C for 2 min. The supernatant was removed, and the
beads were washed carefully four times with immuno-
precipitation buffer. Finally, the beads were resuspendedin 5 × SDS sample buffer (125 mM Tris-HCl [pH 6.8],
4% SDS, 20% glycerol, and 2% β-mercaptoethanol) and
analyzed by Western blotting.
Western blotting
Total cell lysates were prepared using lysis buffer con-
taining 50 mM (pH 7.4) Tris-HCl, 1% Nonidet P-40,
150 mM NaCl, 2.5% deoxycholate, 1 mM phenylmethyl-
sulfonyl fluoride, and protease inhibitor (Roche). Cell
lysates were mixed with 5 × SDS sample buffer and then
loaded on a gel for SDS-PAGE. Proteins were subse-
quently transferred to a polyvinylidene difluoride mem-
brane (Millipore). The membrane was blocked with 5%
nonfat milk and incubated with primary antibodies at 4°C
overnight. The primary antibodies used were anti-Flag M2
(Sigma), anti-V5 (Invitrogen), anti-NUCKS1 (Novus
Biologicals), anti-p65 subunit of NF-κB (Cell Signaling
Technology), anti-IκB-α (Cell Signaling Technology),
anti-CycT1 (Santa Cruz Biotechnology), anti-β-actin
(Sigma), anti-α-tubulin (Sigma), and anti-lamin B (Santa
Cruz Biotechnology). The secondary antibodies used were
rabbit anti-mouse antibody and goat anti-rabbit antibody
(both from Sigma) conjugated with horseradish peroxidase
(HRP). ECL Western blotting detection reagents (Millipore)
were used for signal detection with HRP-conjugated
anti-mouse and anti-rabbit IgG. Chemiluminescence
was visualized using Image Lab™ software (Bio-Rad) ac-
cording to the manufacturer’s protocols. The relative in-
tensities of the NUCKS1 proteins were measured using
the Fujifilm Image Gauge V 4.0 programme (Fujifilm).
Chromatin immunoprecipitation (ChIP) assay and
quantitative real-time PCR
The ChIP assay was performed in HeLa and TZM-bl
cells using a ChIP assay kit (Cell Signaling Technology)
according to the manufacturer’s protocol. Briefly, cells
were transfected with Tat-expressing plasmid (pcDNA3–
Flag–Tat) after knockdown of NUCKS1. Chromatin was
then obtained from the formaldehyde-fixed cells, and
the chromatin was immunoprecipitated with anti-Flag
antibody or control mouse IgG antibody. The eluted ma-
terial was reverse cross-linked, and DNA was precipitated
with ethanol and isolated by spin column purification. The
purified DNA was then analyzed by real-time PCR using
primer sets corresponding to the TAR region of the HIV-1
LTR. The primers used were TAR-F, 5’-AGCTTTCTAC
AAGGGACTTTCCGC-3’ and TAR-R, 5’-ATTGAGGCT
TAAGCAGTGGGTTCC-3’. Real-time PCR was per-
formed using a SYBR Green PCR kit (TAKARA) in a 7500
Real-Time PCR System (Applied Biosystems (ABI)) using
7500 software, version 2.0.1. Melting curve analysis was
performed to ensure the amplification of a single product.
The data were analyzed according to the comparative
Ct method, were normalized to the IgG control, and are
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control siRNA. Relative quantification (RQ) = 2 –ΔΔCt,
where ΔCt = CtTarget– CtControl, and ΔΔCt = ΔCttreated–
Ctuntreated.
Gene expression microarray data analysis
Gene expression microarray analysis was performed using
the Illumina Human HT-12 v4 Expression BeadChip
(Illumina). The Illumina Total Prep RNA Amplification
Kit (Ambion) was used to prepare biotinylated cRNAs
from 0.55 μg of total RNA. After fragmentation, 0.75 μg
of cRNAs were mixed with hybridization buffer and hy-
bridized to the BeadChip. Following incubation in the
hybridization oven, the hybridized arrays were washed.
The microarray images were scanned using the Illumina
Bead array Reader Confocal Scanner. Array data export
processing was performed using Illumina GenomeStudio
v2009.2 (Gene Expression Module v1.5.4). All datasets
were normalized using the quantile normalization method.
Average values were used for replicated data sets.
The Z-score was calculated by subtracting the popu-
lation mean from an individual expression value and
then dividing the difference by the population stand-
ard deviation (SD).
mRNA-Sequencing
The total RNA was extracted using Tri-solution (BSK),
and the mRNA was isolated using an Oligotex mRNA
mini kit (Qiagen). The fragmented mRNA was converted
into cDNA using a random hexamer and Superscript III
reverse transcriptase (Invitrogen). Following our previous
study [57], the mRNA sequencing library was constructed
and sequenced on the Genome Analyzer IIx (Illumina).
Sequencing reads were aligned by the TopHat v2.0.9 align-
ment program [58] to the human reference sequence
(hg18 RefSeq). The RPKM (Reads Per Kilobase of exon per
Million aligned tags) values for each transcript were calcu-
lated by normalizing with the length of the gene transcript
and the total number of aligned tags.
Quantitative RT- PCR
The total RNA was extracted using Tri-solution (BSK),
and the mRNA was isolated using an Oligotex mRNA
mini kit (Qiagen). The mRNA was converted into cDNA
using a random hexamer and Superscript III reverse
transcriptase (Invitrogen). PCR was carried out using








For HIV-1 production assays in a single round, HeLa
cells (2 × 105 cells/well) were transfection with siRNA as
described above. After 24 h, the cells were transfected
with pNL4-3 (300 ng) or pAD8 (300 ng). One day after
transfection, virus-containing supernatants were harvested
every day for 5 days and filtered to remove debris. The
amount of virions in the supernatants was determined
using an HIV-1 p24 enzyme-linked immunosorbent assay
(ELISA) kit (PerkinElmer) according to the manufacturer’s
protocol with minor modification. Briefly, all samples were
diluted in medium, and 200 μl of each diluted sample was
used for the assay. The culture medium from untrans-
fected cells was used as the negative control. The results
were quantified by plotting absorbance values and
comparing these with a standard curve. All assays were
performed in triplicate. The data are represented as
mean ± SD (n = 3).Viral replication assay
1 × 106 293 T cells cells were transfected with 2 μg of
pNL4-3. Three days after the transfection, virus-containing
supernatants were harvested. The amount of virions in the
supernatants was determined using an HIV-1 p24 enzyme-
linked immunosorbent assay (ELISA) kit (PerkinElmer).
For HIV-1 infection, 1 × 106 Jurkat and A3.01 cells were
re-suspended with 0.5 μg of pNL4-3 and centrifuged at
2,500 rpm for 90 min at 30°C. Five days after infection,
the amount of virions in the supernatants was deter-
mined by HIV-1 p24 ELISA kit.Statistical analysis
The data were analysed for statistical significance and
expressed as mean values ± SD. The mean values were
compared using Student’s t-test with GraphPad Instat
Software. P-values of < 0.05 were considered statistically
significant.Additional files
Additional file 1: Figure S1. The association between NUCKS1 and Tat
binding to TAR RNA. (A–B) The HeLa cells transiently transfected with
HIV-1 LTR (A) or TZM-bl cells containing an integrated HIV-1 LTR (B) were
transfected with control siRNA or three individual NUCKS1 siRNAs. At 24
h after knockdown, these cells were transiently transfected with the
Flag–Tat expression plasmid and cultured for an additional 24 h. The cells
were cross-linked with formaldehyde, and chromatin immuno-precipitation
was performed using IgG control or anti-Flag antibodies. Quantitative
real-time PCR was performed with the primer sets corresponding to the
upstream and downstream of the TAR region of the HIV-1 LTR. PCR was
carried out using the following primers; TAR-F: 5’-AGCTTTCTACAAGG
GACTTTCCGC-3’ and TAR-R, 5’-ATTGAGGCTTAAGCAGTGGGTTCC-3’. Up
TAR-F: 5’-CACACAAGGCTACTTCCCTGA-3’, Up TAR-R: 5’-GGCCATGTGAT
GAAATGCTA-3’, Down TAR-F: 5’-TGTGTGCCCGTCTGTTGTGT-3’, Down
TAR-R: 5’ -CCTGCGTCGAGAGAGCTC-3’. ; the data were normalized to the
IgG control antibodies and are expressed as the fold change of Tat
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data were expressed as mean ± SD (n=3).
Additional file 2: Figure S2. The mRNA expression values for
Tat-binding genes in ACH-2 cells by PMA treatment. The RPKM (Reads
Per Kilobase of exon model per Million aligned tags) was calculated for
each transcript. The expression value for the ACH-2 control is shown in
white, the ACH-2 PMA in black.
Additional file 3: Table S1. Functional annotations for the significant
DEGs in PMA-treated ACH-2 cells.
Additional file 4: Figure S3. Bisulfite sequencing of CpG island in
NUCKS1 the promoter region of ACH-2 cells. The PCR region includes 13
individual CpG sites from -1160 bp to -983 bp relative to the transcription
start site of the NUCKS1 gene. The open circles represent un-methylated
CpG, while the filled circle represents methylated CpG. UT; PMA-untreated.
Additional file 5: Figure S4. The level of NUCKS1 in resting and
activated primary CD4+ T cells. The resting CD4+ T cells isolated from
PBMCs were activated with anti-CD3/CD28 antibodies and IL-2 for 1 h.
Nucleus and cytoplasm were fractionated and protein level was assessed
by Western blotting using anti-p65, -Iκb, and -NUCKS1 antibodies. The
nuclear and cytoplasmic fractions were evaluated using anti-lamin B and
-tubulin antibodies, respectively.
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